Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Candel Therapeutics Inc
(NQ:
CADL
)
5.680
+0.370 (+6.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Candel Therapeutics Inc
< Previous
1
2
Next >
Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024
June 13, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
June 08, 2023
Nicoletta Loggia, PhD, RPh, biopharma executive with more than two decades of technical expertise in the biopharmaceutical industry
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference
June 05, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 19, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 11, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO
May 02, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer
April 17, 2023
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA review of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small...
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
March 30, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Participate in Guggenheim Healthcare Talks 2023 Oncology Day
February 01, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Participate in Upcoming B. Riley Oncology Conference
January 12, 2023
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics R&D Day Presentations Spotlight its Advanced Pipeline and Capabilities to Develop Novel Viral Immunotherapies for Patients with Cancer
December 06, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
November 29, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting
November 18, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Late-Breaking Oral Presentation at SITC Annual Meeting with Data on CAN-2409 in Combination with Nivolumab in a Phase 1 Mechanistic Clinical Trial in Patients with High-Grade Glioma
November 11, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 10, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Announces Upcoming Clinical Data Presentations at SITC and SNO
November 07, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Upcoming Investor Conference Participation for November
November 01, 2022
From
Candel Therapeutics
Via
GlobeNewswire
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
October 26, 2022
From
Candel Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.